Every second of every day, your immune system makes life-or-death decisions. Attack this cell. Protect that one. Destroy this invader. Leave that tissue alone. Get it wrong, and your own defenses could turn against you, destroying organs and tissues in a cascade of friendly fire that doctors call autoimmune disease.
Join a community of 14,000,000+ Seekers!
Subscribe to unlock exclusive insights, wisdom, and transformational tools to elevate your consciousness. Get early access to new content, special offers, and more!
Yet somehow, most people never experience this catastrophic failure. Your immune system creates billions of T cells capable of recognizing virtually any threat, including patterns that match your own cells. By design, your body builds weapons that could destroy you. So why doesn’t it?
For decades, scientists thought they knew the answer. They believed dangerous cells were eliminated during development in an organ called the thymus. Problem solved. Case closed. But experiments kept producing results that didn’t fit this neat explanation. Mice that should have developed weak immune systems instead developed ones that went berserk, attacking their own organs with devastating effect.
Three scientists refused to accept the incomplete answer. They spent years pursuing a hypothesis many colleagues dismissed. Their discoveries revealed that our immune system operates with a secret security force, invisible guards that constantly patrol and prevent disaster. In October 2025, Mary Brunkow, Fred Ramsdell, and Shimon Sakaguchi won the Nobel Prize in Physiology or Medicine for solving one of biology’s most dangerous puzzles.
The Autoimmune Paradox: When Your Protector Becomes Your Enemy
Your immune system represents an evolutionary masterpiece. Every day, it protects you from thousands of different viruses, bacteria, and microbes attempting to invade. White blood cells called T cells patrol constantly, each carrying unique receptors that function like molecular sensors. When a receptor detects a matching pattern on a cell surface, it triggers an immune response.
Here’s where evolution created a problem. Your body generates T cell receptors by randomly combining genes, creating more than a quadrillion possible variations. This enormous diversity ensures that no matter what new pathogen emerges, some T cells will recognize it. When COVID-19 appeared in 2019, people’s immune systems could respond because random chance had already created T cells capable of detecting this novel virus.
But random generation inevitably produces some receptors that match patterns on your own healthy cells. Without regulation, these self-recognizing T cells would attack your organs, causing autoimmune diseases like lupus, rheumatoid arthritis, multiple sclerosis, or Type 1 diabetes.
Millions of people suffer from autoimmune conditions, yet billions don’t. Why do most immune systems successfully distinguish friend from foe, while some fail catastrophically?
Old Answer: Central Tolerance and the Thymus Test
By the 1980s, scientists believed they understood immune regulation. As T cells mature in the thymus gland, they undergo testing that eliminates dangerous self-recognizing cells. Researchers called this process central tolerance, and it seemed to explain how the body prevented autoimmune disaster.
Some scientists suspected additional mechanisms might exist. They hypothesized about “suppressor T cells” that dealt with dangerous cells escaping the thymus test. But evidence supporting this idea proved flawed or fabricated. When the hypothesis collapsed, researchers abandoned the entire concept.
Central tolerance appeared sufficient. Scientists moved on to other questions. But one researcher in Japan kept encountering results that didn’t make sense within this framework.
One Scientist Swims Against the Tide in 1990s Japan
Shimon Sakaguchi at the Aichi Cancer Center Research Institute in Nagoya couldn’t shake a puzzling observation. His colleagues had surgically removed the thymus gland from newborn mice, expecting the animals would develop fewer T cells and weaker immune systems.
Instead, when surgery occurred three days after birth, the opposite happened. Immune systems went into overdrive, attacking the mice’s own organs and causing multiple autoimmune diseases. Something was protecting mice from autoimmune disease, and that something developed in the first few days after birth.
Sakaguchi isolated T cells from healthy mice and injected them into mice without thymus glands. Remarkably, the transferred cells protected recipients from autoimmune disease. Certain T cells could apparently calm the immune system and prevent self-attack.
Scientists had rejected the idea of suppressor cells, but Sakaguchi’s experiments suggested they existed under a different identity. He spent over a decade searching for these mysterious protectors.
1995 Breakthrough: Discovery of Regulatory T Cells
Scientists distinguish different T cell types by proteins on their surfaces. Helper T cells carry a protein called CD4. Killer T cells display CD8. Sakaguchi’s protective cells came from the CD4 group, yet they suppressed immune responses instead of amplifying them.
In 1995, Sakaguchi published his discovery in the Journal of Immunology. He had identified a new class of T cells characterized by carrying both CD4 and another protein called CD25 on their surfaces. These regulatory T cells calmed the immune system rather than activating it.
Many scientists remained skeptical. Discovering a new cell type required extraordinary evidence. Sakaguchi needed more proof, and that proof would come from an unexpected source: sick mice born in a Tennessee laboratory during the Manhattan Project.
Meanwhile in Tennessee: Mystery of the Scurfy Mice Since 1940s
In the 1940s, researchers at Oak Ridge National Laboratory were studying radiation effects as part of atomic bomb development. Among their experimental mice, some males were unexpectedly born with scaly, flaky skin, enormously enlarged spleens and lymph glands, and lifespans of just a few weeks.
Scientists named the strain “scurfy” and discovered the mutation causing these symptoms resided on the X chromosome. Males, with only one X chromosome, developed the disease when they inherited the mutation. Females, with two X chromosomes, remained healthy as long as one chromosome carried normal DNA. These carrier females passed the scurfy mutation to new generations.
By the 1990s, researchers understood that T cells were attacking the scurfy mice’s organs, causing the devastating symptoms. But nobody knew which gene mutation triggered this autoimmune rebellion.
Brunkow and Ramsdell’s Detective Work: Finding One Gene Among 170 Million
Mary Brunkow and Fred Ramsdell worked at Celltech Chiroscience, a biotech company developing treatments for autoimmune diseases. Understanding the molecular mechanism behind scurfy mice could provide crucial insights into how autoimmune diseases arise in humans.
They decided to find the mutant gene responsible. Today, scientists can map entire genomes in days. In the 1990s, finding a single mutation among the 170 million base pairs forming the mouse X chromosome required years of painstaking work.
Brunkow and Ramsdell narrowed the search to about 500,000 nucleotides, then began detailed mapping of that region. They identified twenty potential genes and systematically compared each one in healthy and scurfy mice.
After years of dedicated effort, they found their answer in the twentieth gene. Mary Brunkow later recalled: “It was really a molecular slog, to get to that exact mutation. It was just a very small genetic alteration that results in quite a profound change in the immune system.”
The Foxp3 Gene: Missing Piece That Explained Everything
Brunkow and Ramsdell named their discovery Foxp3, after the forkhead box gene family. These genes regulate other genes’ activity, affecting cell development. But was this mouse gene relevant to human disease?
During their research, they had suspected that IPEX, a rare X-linked autoimmune disease in boys, might be the human version of the scurfy condition. Working with pediatricians worldwide, they collected samples from boys with IPEX and found harmful mutations in the human FOXP3 gene.
In 2001, they published their findings in Nature Genetics. Mutations in the FOXP3 gene caused both IPEX in humans and scurfy disease in mice. This discovery triggered intense research activity as scientists realized Foxp3 might control the regulatory T cells Sakaguchi had discovered.
Connecting the Dots: How Foxp3 Creates Regulatory T Cells
Two years later, Sakaguchi proved that the Foxp3 gene controls regulatory T cell development. The gene is expressed specifically in these cells, and experiments showed that activating Foxp3 in other T cell types could convert them into regulatory cells.
Researchers examining scurfy mice found that regulatory T cells were absent. Without functional Foxp3, mice couldn’t produce the security guards needed to prevent immune system attacks on their own tissues.
Scientists now understand the complete picture. Random gene recombination creates T cells capable of attacking anything, including the body’s own organs. Central tolerance eliminates many dangerous cells during thymus development. But some escape this filter, making peripheral immune tolerance essential. Regulatory T cells, controlled by the Foxp3 gene, patrol constantly and prevent escaped self-recognizing cells from causing autoimmune disease.
How These Cellular Security Guards Actually Work
Regulatory T cells function as the immune system’s brakes. They monitor other immune cells and intervene when attacks threaten the body’s own tissues. After the immune system eliminates an invader, regulatory cells ensure the response calms down rather than continuing at full intensity.
Olle Kämpe, chair of the Nobel Committee, explained the significance: “Their discoveries have been decisive for our understanding of how the immune system functions and why we do not all develop serious autoimmune diseases.”
The balance between attack and tolerance determines whether the immune systems protect health or destroys it. Too little regulatory activity allows autoimmune disease. Too much suppresses responses needed to fight infections and cancer.
From Discovery to Treatment: Over 200 Clinical Trials Launched
Understanding regulatory T cells opened new treatment strategies. More than 200 clinical trials now test therapies based on the laureates’ discoveries.
Cancer researchers work to reduce regulatory T cell activity around tumors, where these cells create protective barriers preventing immune attacks on cancer cells. Removing this protection could help immune systems eliminate tumors more effectively.
For autoimmune diseases, scientists take the opposite approach, boosting regulatory T cell numbers to suppress harmful inflammation. Some trials use interleukin-2, a naturally occurring compound that promotes regulatory T cell growth. Companies are developing engineered regulatory T cells with specific targets, allowing precision control over immune responses.
Organ transplant patients might benefit from increased regulatory T cell activity, preventing rejection of donor organs. Researchers are testing whether regulatory cells can be isolated from patients, multiplied in laboratories, and returned to create stronger immune tolerance.
Three Scientists Share $1.1 Million Nobel Prize
When the 2025 Nobel Prize announcement came, Sakaguchi in Japan called it a happy surprise. Ramsdell, who co-founded Sonoma Biotherapeutics, learned about his prize after returning from a backpacking trip in Idaho, where colleagues couldn’t reach him.
Sakaguchi acknowledged the collaborative nature of scientific discovery: “I was never working alone—there were people all over the world who shared similar ideas. I see this award as one that represents all of those people who have contributed to this research alongside me.”
Colleagues particularly celebrated recognition for Mary Brunkow, who some felt hadn’t always received appropriate credit for her contributions. Now a researcher at the Institute for Systems Biology in Seattle, she shares the approximately $1.1 million prize equally with her co-laureates.
From Mouse Experiments to Life-Saving Treatments for Millions
Three scientists pursuing curiosity-driven questions about mouse biology and immune cell development opened pathways to treatments that could revolutionize medicine. Their discoveries explain why most people avoid autoimmune diseases while revealing how to help those who don’t.
Clinical applications are already emerging. Patients in trials are receiving therapies designed to dial immune responses up or down with precision previously impossible. Some treatments show remarkable results, while others require refinement. But all trace back to basic scientific questions about how bodies regulate themselves.
Science often works this way. Researchers pursuing fundamental biology questions make discoveries that seem abstract until decades later, when medical applications emerge. Sakaguchi began his work in the 1980s. Brunkow and Ramsdell published their gene discovery in 2001. Only now are treatments reaching patients.
Support for basic research remains essential. Today’s abstract questions about cellular mechanisms become tomorrow’s life-saving therapies. Understanding how regulatory T cells prevent autoimmune disease took persistence, curiosity, and a willingness to challenge prevailing scientific consensus. Nobel Prizes celebrate these qualities while reminding us that medical breakthroughs often begin with simple questions about how living things work.
28
0
0
0
How do I get into the study? Have Anca Vasculitis.
Was wondering the same. Rheumatoid Arthritis for me.